Clinical Trials Browser

Phase 2 × Hypopharyngeal Neoplasms × tislelizumab × Clear all

NCT06554028 2024-08-14

Tislelizumab and Induction Chemotherapy for Larynx Preservation in Resectable Advanced Laryngeal/Hypopharyngeal Cancer

Phase 2 Not yet recruiting

Hypopharyngeal Neoplasms, Laryngeal Neoplasms